Ineligible, Unaware, or Uninterested? Associations Between Underrepresented Patient Populations and Retention in the Pathway to Cancer Clinical Trial Enrollment

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Jesse Sussell

Employment: Genentech

Stock and Other Ownership Interests: Roche

Shilpen Patel

Employment: Genentech/Roche

Stock and Other Ownership Interests: Genentech/Roche

Research Funding: Genentech

Travel, Accommodations, Expenses: Genentech

Rebecca Arend

Employment: Signatera (I)

Consulting or Advisory Role: VBL Therapeutics, GlaxoSmithKline, Merck, Seagan, Sutro Biopharma, KIYATEC, Caris Life Sciences, Leap Therapeutics

Research Funding: Champions Oncology, Exelixis, GlaxoSmithKline, Immunogen, Merck

Travel, Accommodations, Expenses: Caris Life Sciences, GlaxoSmithKline, VBL Therapeutics

Gabrielle B. Rocque

This author is an Associate Editor for JCO Oncology Practice. Journal policy recused the author from having any role in the peer review of this manuscript.

Consulting or Advisory Role: Pfizer, Flatiron Health, Gilead Sciences

Research Funding: Carevive Systems, Genentech, Pfizer

Travel, Accommodations, Expenses: Gilead Sciences

No other potential conflicts of interest were reported.